Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–447 of 447 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: IV Fluids Clear all

Conditions: Traumatic Brain Injury
Interventions: Premarin IV, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Lymphoma
Interventions: filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 104
States / cities: Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more

Conditions: Lymphoma
Interventions: bevacizumab, cyclophosphamide, doxorubicin, prednisone, vincristine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 110
States / cities: Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more

Conditions: Traumatic Brain Injury (TBI) Patients
Interventions: Normal Saline (0.9% NaCl), balanced crystalloid; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Chronic Lung Disease
Interventions: Lyophilized Palivizumab, Liquid Palivizumab; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: Up to 24 Months
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 54
States / cities: Birmingham, Alabama • Hoover, Alabama • Tuscaloosa, Alabama + 45 more

Conditions: Twin Twin Transfusion Syndrome
Interventions: Selective Laser Photocoagulation of Communicating Vessels; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hemorrhagic Shock, Peritonitis
Interventions: Advanced Life Support; Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions: Biocidin REMOVE, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony
Interventions: Calcium Gluconate, Saline; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Coronary Artery Disease (CAD), Ischemic Heart Disease
Interventions: Flurpiridaz (18F) Injection; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 5
States / cities: Hialeah, Florida • Miami, Florida • North Miami Beach, Florida + 2 more

Conditions: Drain Output After Breast Reduction Surgery, Breast Reductions
Interventions: IV TXA, Topical TXA, Topical saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Headache
Interventions: Normal Saline 5mL, Normal Saline 20mL/kg, Prochlorperazine 0.15 mg/kg up to 10 mg IV, Diphenhydramine 1 mg/kg up to 50 mg IV; Drug
Lead sponsor: University Medical Center of Southern Nevada; Other
Eligibility: 10 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Post-Treatment Lyme Disease
Interventions: Ceftriaxone (Rocephin®), Dextrose 5% (D5W); Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Saakshi Khattri; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Saline Versus Balanced Crystalloid in Traumatic Brain Injury

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Philadelphia Immediate Transport in Penetrating Trauma Trial

Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

Intravenous Fluids in Benign Headaches Trial

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis